London, UK, 15 Dec 2025 - Laverock Therapeutics announces appointment of Lisa Deschamps to the board.
We are pleased to announce the appointment of Lisa Deschamps to the Laverock board. Lisa brings extensive experience in drug development and commercialization across different therapeutic areas and modalities. Lisa is currently CEO of AviadoBio, a clinical stage AAV gene therapy company focused on neurodegenerative diseases. Prior to this, she was SVP and CBO of Novartis Gene Therapies, managing their extensive gene therapy portfolio, including the world-wide commercialization of Zolgensma.
Lisa currently serves on the Boards of the Alliance of Regenerative Medicine and Biotechnology Innovation Organization. Lisa previously served on the board of VERONA Pharma prior to its acquisition in Oct. 2025 by Merck for $10 Billion.
Laverock recently announced progress in the validation of its programmable gene control platform in macrophages and T cells. Data demonstrating it’s ability to control the polarisation state of an iPSC derived macrophage in the tumour microenvironment, as well as regulate a delivered payload, sets it on-course in the development of a best in class macrophage therapy for solid tumours. In T cells, autoregulation of checkpoint pathway control and CAR expression has been shown in vivo to result in increased tumour clearance and T cell persistence, and decreased cell exhaustion.
The company is now moving towards a product development phase with opportunities to apply its platform in oncology, fibrosis, metabolic disease and genetic disease either through its own development or with partners.
Lisa Deschamps, said: “I’m thrilled to be joining Laverock’s board at such an exciting time. The recent progress on the validation of the gene control platform has tremendous potential — from oncology to broader applications. I look forward to working with Laverock’s strong leadership team and the board to build a differentiated pipeline that addresses critical unmet needs."
David Venables, CEO of Laverock, said: “We are excited to welcome Lisa to the Laverock board and look forward to working with her as we progress towards clinical development. Lisa’s extensive experience will be invaluable in supporting and guiding us on this journey.”
ENDS
For further information please contact:
Laverock Therapeutics
E: contact@laverocktx.com
Notes to Editors
About Laverock Therapeutics
Laverock Therapeutics is powering the development of disease-responsive advanced therapies through our unique, programmable gene control technology. Our innovative platform harnesses the cell’s natural regulatory mechanisms to deliver programmable and tunable gene control through recoded miRNAs. This enables the development of highly effective medicines with enhanced precision and improved safety profiles.
Utilising our platform technologies, we are working to develop the next-generation of advanced therapies, both through our own pipeline – targeting oncology and genetic medicine – and through partnerships.
Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock has raised more than £20m seed funding to date from high-calibre investors including Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos Advisory, UK Innovation & Science Seed Fund, Tekfen Ventures and Norcliffe Capital.
